High Expression of MicroRNA-196a is Associated with Progression of Hepatocellular Carcinoma in Younger Patients.
liver cancer
microRNA
recurrence
stemness
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Oct 2019
13 Oct 2019
Historique:
received:
30
08
2019
revised:
10
10
2019
accepted:
11
10
2019
entrez:
17
10
2019
pubmed:
17
10
2019
medline:
17
10
2019
Statut:
epublish
Résumé
MicroRNAs are small RNAs involved in various biological processes and cancer metastasis. miR-196a was associated with aggressive behaviors in several cancers. The role of miR-196a in hepatocellular carcinoma (HCC) metastasis remains unknown. This study aimed to examine the role of miR-196a in HCC progression. Expression of miR-196a was measured in 83 human HCC samples. The HCC patients with high miR-196a expression had younger ages, lower albumin levels, higher frequency with alpha-fetoprotein (AFP) levels ≥20 ng/mL, more macrovascular invasion, and non-early stages. Kaplan-Meier analysis showed that high miR-196a expression was associated with lower recurrence-free survival. Knockdown of miR-196a decreased transwell invasiveness, sphere formation, transendothelial invasion, and Slug, Twist, Oct4, and Sox2 expression, suppressed angiogenesis, and reduced sizes of xenotransplants and number of pulmonary metastasis. Down-regulation of miR-196a decreased Runx2 and osteopontin (OPN) levels. Knockdown of Runx2 in vitro resulted in comparable phenotypes with miR-196a down-regulation. Restoration of Runx2 in miR-196a-knockdown HCC reverted tumor phenotypes. This study showed that high expression of miR-196a is associated with HCC progression in a subset of younger patients. miR-196a mediates HCC progression via upregulation of Runx2, OPN, epithelial-mesenchymal transition (EMT) regulators, and stemness genes. We proposed that miR-196a can be used as a prognostic marker and a potential therapeutic target.
Identifiants
pubmed: 31614906
pii: cancers11101549
doi: 10.3390/cancers11101549
pmc: PMC6826650
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Taipei Veterans General Hospital, Taiwan
ID : TVGH V97ER2-016
Organisme : Taipei Veterans General Hospital, Taiwan
ID : VGHUST105-G7-2-1
Organisme : Taipei Veterans General Hospital, Taiwan
ID : VGHUST106-G7-2-1
Organisme : Taipei Veterans General Hospital, Taiwan
ID : VGHUST107-G1-2-1
Organisme : Taipei Veterans General Hospital, Taiwan
ID : MOHW107-TDU-B-211-114019
Organisme : Taipei Veterans General Hospital, Taiwan
ID : MOHW108-TDU-B-211-124019
Organisme : Ministry of Science and Technology, Taiwan
ID : NSC98-3112-B-010-017
Organisme : Ministry of Science and Technology, Taiwan
ID : NSC99-3112-B-010-017
Organisme : Ministry of Science and Technology, Taiwan
ID : NSC100-2325-B-010-003
Organisme : Ministry of Education, Taiwan
ID : 107CRC-T206
Organisme : Ministry of Education, Taiwan
ID : 108-CRC-T205
Références
Nature. 2005 Feb 17;433(7027):769-73
pubmed: 15685193
Oncol Lett. 2019 Feb;17(2):1859-1864
pubmed: 30675248
Mol Cell Biol. 2007 May;27(9):3337-52
pubmed: 17325044
Breast Cancer Res Treat. 1995;36(2):169-80
pubmed: 8534865
Nucleic Acids Res. 2014 Jan;42(Database issue):D68-73
pubmed: 24275495
Cancer. 2003 Jul 1;98(1):119-27
pubmed: 12833464
Semin Liver Dis. 2005;25(2):181-200
pubmed: 15918147
Hepatology. 2009 Nov;50(5):1464-74
pubmed: 19821482
Nature. 2016 Jan 21;529(7586):298-306
pubmed: 26791720
Nature. 2008 Oct 23;455(7216):1124-8
pubmed: 18806776
Oncogene. 2008 Nov 6;27(52):6667-78
pubmed: 18663355
Dig Liver Dis. 2007 Feb;39(2):167-72
pubmed: 17161983
J Gen Virol. 1981 Mar;53(Pt 1):105-13
pubmed: 6268737
Hepatology. 2008 Mar;47(3):897-907
pubmed: 18176954
Nucleic Acids Res. 2018 Jan 4;46(D1):D296-D302
pubmed: 29126174
J Biol Chem. 1999 May 7;274(19):13711-7
pubmed: 10224145
Ann N Y Acad Sci. 2016 Nov;1383(1):80-87
pubmed: 27526290
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Nucleic Acids Res. 2018 Sep 6;46(15):e93
pubmed: 29905834
Expert Opin Pharmacother. 2015;16(18):2719-25
pubmed: 26513009
Oncol Lett. 2016 Nov;12(5):4041-4047
pubmed: 27895768
Oncogene. 2006 Apr 20;25(17):2537-45
pubmed: 16331254
J Surg Res. 2004 Oct;121(2):228-41
pubmed: 15501463
Arch Surg. 2012 Feb;147(2):137-44
pubmed: 22006855
Ann Surg Oncol. 2012 Jul;19 Suppl 3:S455-63
pubmed: 21822558
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Hepatol Commun. 2018 Sep 28;2(11):1392-1407
pubmed: 30411085
J Biol Chem. 2003 Dec 5;278(49):48684-9
pubmed: 14506237
J Bone Miner Res. 2009 May;24(5):816-25
pubmed: 19063684
J Cell Mol Med. 2011 Jan;15(1):14-23
pubmed: 21091634
Liver Int. 2006 Sep;26(7):766-73
pubmed: 16911457
J Clin Med. 2016 Jan 14;5(1):null
pubmed: 26784241
Cell. 1997 May 30;89(5):755-64
pubmed: 9182763
J Gastroenterol. 2008;43(11):881-8
pubmed: 19012042
Biochim Biophys Acta. 2008 Mar;1778(3):660-9
pubmed: 17854762
BMC Genomics. 2013 Oct 26;14:736
pubmed: 24160375
Cancer Res. 2008 Mar 1;68(5):1451-61
pubmed: 18316609
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Ann Hepatol. 2011 Jul-Sep;10(3):296-305
pubmed: 21677331
Oncogene. 2013 Jan 17;32(3):296-306
pubmed: 22370643
Nat Rev Endocrinol. 2012 Jan 31;8(4):212-27
pubmed: 22290358
Mol Cancer Ther. 2012 Apr;11(4):842-52
pubmed: 22343731
Dig Dis Sci. 2015 Nov;60(11):3351-63
pubmed: 26123838